{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:16:09Z","timestamp":1791353769261,"version":"4.3.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2016,4,16]],"date-time":"2016-04-16T00:00:00Z","timestamp":1460764800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"National Natural Science Foundation of China (CN)","award":["81370637"],"award-info":[{"award-number":["81370637"]}]},{"name":"National Institute of Health Research (NIHR) Biomedical Research Centre funding scheme"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1007\/s00432-016-2159-7","type":"journal-article","created":{"date-parts":[[2016,4,16]],"date-time":"2016-04-16T12:50:37Z","timestamp":1460811037000},"page":"1539-1547","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Young age and high cost are associated with future preference for stopping tyrosine kinase inhibitor therapy in Chinese with chronic myeloid leukemia"],"prefix":"10.1007","volume":"142","author":[{"given":"Qian","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng-Chen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song-Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Peter","family":"Gale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,4,16]]},"reference":[{"key":"2159_CR1","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(13)62120-0","volume":"385","author":"JF Apperley","year":"2015","unstructured":"Apperley JF (2015) Chronic myeloid leukemia. Lancet (London, England) 385:1447\u20131459","journal-title":"Lancet (London, England)"},{"key":"2159_CR2","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/00005650-200003000-00010","volume":"38","author":"NK Arora","year":"2000","unstructured":"Arora NK, McHorney CA (2000) Patient preferences for medical decision making: who really wants to participate? Med Care 38:335\u2013341","journal-title":"Med Care"},{"key":"2159_CR3","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Blood 122:872\u2013884","journal-title":"Blood"},{"key":"2159_CR4","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.canlet.2014.01.033","volume":"347","author":"M Breccia","year":"2014","unstructured":"Breccia M, Alimena G (2014) Discontinuation of tyrosine kinase inhibitors and new approaches to target leukemic stem cells: treatment-free remission as a new goal in chronic myeloid leukemia. Cancer Lett 347:22\u201328","journal-title":"Cancer Lett"},{"issue":"6","key":"2159_CR5","doi-asserted-by":"crossref","first-page":"e100435","DOI":"10.1371\/journal.pone.0100435","volume":"9","author":"L Brom","year":"2014","unstructured":"Brom L, Pasman HRW, Widdershoven GAM et al (2014) Patients\u2019 preferences for participation in treatment decision-making at the end of life: qualitative interviews with advanced cancer patients. PLoS One 9(6):e100435","journal-title":"PLoS One"},{"key":"2159_CR6","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2009.25.3724","volume":"28","author":"JE Cortes","year":"2010","unstructured":"Cortes JE, Baccarani M, Guilhot F et al (2010) Phase III, randomized, open-label study of daily imatinib mesylate 400\u00a0mg versus 800\u00a0mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol 28:424\u2013430","journal-title":"J Clin Oncol"},{"key":"2159_CR7","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1200\/JCO.2013.52.9123","volume":"32","author":"SB Dusetzina","year":"2014","unstructured":"Dusetzina SB, Winn AN, Abel GA, Huskamp HA, Keating NL (2014) Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol 32:306\u2013311","journal-title":"J Clin Oncol"},{"key":"2159_CR8","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1182\/blood-2011-04-347575","volume":"118","author":"F Efficace","year":"2011","unstructured":"Efficace F, Baccarani M, Breccia M et al (2011) Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood 118:4554\u20134560","journal-title":"Blood"},{"key":"2159_CR9","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/jnci\/djr060","volume":"103","author":"C Gambacorti-Passerini","year":"2011","unstructured":"Gambacorti-Passerini C, Antolini L, Mahon F-X et al (2011) Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst 103:553\u2013561","journal-title":"J Natl Cancer Inst"},{"key":"2159_CR10","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/ajh.22019","volume":"86","author":"P Ganesan","year":"2011","unstructured":"Ganesan P, Sagar TG, Dubashi B et al (2011) Non-adherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia. Am J Hematol 86:471\u2013474","journal-title":"Am J Hematol"},{"key":"2159_CR11","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1182\/blood-2010-10-309807","volume":"117","author":"AR Ibrahim","year":"2011","unstructured":"Ibrahim AR, Eliasson L, Apperley JF et al (2011) Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood 117:3733\u20133736","journal-title":"Blood"},{"key":"2159_CR12","doi-asserted-by":"crossref","unstructured":"Jiang Q, Gale RP (2016) Molecular monitoring of tyrosine kinase inhibitor therapy of chronic myeloid leukemia in China. J Cancer Res Clin Oncol (accepted)","DOI":"10.1007\/s00432-016-2158-8"},{"key":"2159_CR13","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","volume":"12","author":"HM Kantarjian","year":"2011","unstructured":"Kantarjian HM, Hochhaus A, Saglio G et al (2011) Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukemia: 24-month minimum follow-up of the phase 3 randomized ENESTnd trial. Lancet Oncol 12:841\u2013851","journal-title":"Lancet Oncol"},{"key":"2159_CR14","doi-asserted-by":"crossref","first-page":"e2015013","DOI":"10.4084\/mjhid.2015.013","volume":"7","author":"J Kapoor","year":"2015","unstructured":"Kapoor J, Agrawal N, Ahmed R et al (2015) Factors influencing adherence to imatinib in Indian chronic myeloid leukemia patients: a cross-sectional study. Mediterr J Hematol Infect Dis 7:e2015013","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"2159_CR15","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.2147\/PPA.S70712","volume":"8","author":"M Kek\u00e4le","year":"2014","unstructured":"Kek\u00e4le M, Talvensaari K, Koskenvesa P, Porkka K, Airaksinen M (2014) Chronic myeloid leukemia patients\u2019 adherence to per-oral tyrosine kinase inhibitors compared with adherence as estimated by their physicians. Patient Prefer Adherence 8:1619\u20131627","journal-title":"Patient Prefer Adherence"},{"key":"2159_CR16","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/j.leukres.2010.03.033","volume":"34","author":"D-W Kim","year":"2010","unstructured":"Kim D-W, Banavali SD, Bunworasate U et al (2010) Chronic myeloid leukemia in the Asia-Pacific region: current practice, challenges and opportunities in the targeted therapy era. Leuk Res 34:1459\u20131471","journal-title":"Leuk Res"},{"key":"2159_CR17","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/1471-2407-12-152","volume":"12","author":"Y Kodama","year":"2012","unstructured":"Kodama Y, Morozumi R, Matsumura T et al (2012) Increased financial burden among patients with chronic myelogenous leukemia receiving imatinib in Japan: a retrospective survey. BMC Cancer 12:152","journal-title":"BMC Cancer"},{"key":"2159_CR18","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"FX Mahon","year":"2010","unstructured":"Mahon FX, R\u00e9a D, Guilhot J et al (2010) Discontinuation of imatinib in patients with chronic myeloid leukemia who have maintained complete molecular remission for at least 2\u00a0years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11:1029\u20131035","journal-title":"Lancet Oncol"},{"key":"2159_CR19","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","volume":"28","author":"D Marin","year":"2010","unstructured":"Marin D, Bazeos A, Mahon FX et al (2010) Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 28:2381\u20132388","journal-title":"J Clin Oncol"},{"key":"2159_CR20","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s10198-014-0622-4","volume":"16","author":"AC M\u00fchlbacher","year":"2015","unstructured":"M\u00fchlbacher AC, Bethge S (2015) Patients\u2019 preferences: a discrete-choice experiment for treatment of non-small-cell lung cancer. Eur J Health Econ 16:657\u2013670","journal-title":"Eur J Health Econ"},{"key":"2159_CR21","unstructured":"National Comprehensive Cancer Network (2016) NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia version 1. Fort Washington PA. National Comprehensive Care Network. 2015. http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cml.pdf . Accessed 26 March 2016"},{"key":"2159_CR22","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","volume":"113","author":"L Noens","year":"2009","unstructured":"Noens L, Van Lierde MA, De Bock R et al (2009) Prevalence, determinants, and outcomes of non-adherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 113:5401\u20135411","journal-title":"Blood"},{"key":"2159_CR24","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","volume":"109","author":"P Rousselot","year":"2007","unstructured":"Rousselot P, Huguet F, Rea D et al (2007) Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 109:58\u201360","journal-title":"Blood"},{"key":"2159_CR25","doi-asserted-by":"crossref","first-page":"e241","DOI":"10.3747\/co.21.1736","volume":"21","author":"D Sanford","year":"2014","unstructured":"Sanford D, Kyle R, Lazo-Langner A et al (2014) Patient preferences for stopping tyrosine kinase inhibitors in chronic myeloid leukemia. Curr Oncol 21:e241\u2013e249","journal-title":"Curr Oncol"},{"key":"2159_CR26","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1756-9966-29-20","volume":"29","author":"A-H Wang","year":"2010","unstructured":"Wang A-H, Wang Y-Y, Yao Y et al (2010) Summary of 615 patients of chronic myeloid leukemia in Shanghai from 2001 to 2006. J Exp Clin Cancer Res 29:20","journal-title":"J Exp Clin Cancer Res"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-016-2159-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-016-2159-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-016-2159-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T22:40:57Z","timestamp":1559083257000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-016-2159-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,16]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["2159"],"URL":"https:\/\/doi.org\/10.1007\/s00432-016-2159-7","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,16]]}}}